| Literature DB >> 26999227 |
Rizwan Ahmad1, Niyaz Ahmad2, Atta Abbas Naqvi3, Vassiliki Exarchou4, Atul Upadhyay5, Emmy Tuenter6, Kenn Foubert7, Sandra Apers8, Nina Hermans9, Luc Pieters10.
Abstract
Ziziphus oxyphylla and Cedrela Serrata plants have a folkloric use in Pakistan for treatments of different ailments, i.e., Jaundice, Hepatitis, Diabetes, and antimicrobial. Until now, none of the research studies have reported any phytochemical work on leaves of these two plants. This study aimed to isolate and perform phytochemical analysis in order to search for the constituent having the active role in treatment of the aforementioned ailments. A bioassay-guided fractionation and isolation procedure was used to isolate the concerned phytochemicals present in leaf extracts of Z. oxyphylla and C. serrata. The process involved the hyphenated techniques, i.e., Flash Chromatography, Semi-Preparative HPLC/DAD, UPLC/MS, and NMR in order to isolate and elucidate the structure of the phytochemicals. Seven compounds (1-7) were isolated and identified as flavonoids, more in particular glycosides of quercetin and kaempferol. They showed DPPH scavenging activity, compound 3 (isoquercitrin) being the most active one with an IC50 of 10.8 µg/mL (positive control quercetin; IC50 3.6 µg/mL). The superoxide-radical scavenging and total antioxidant (ABTS) assays indicated IC50 values ranging from 200 to 910 µg/mL and 170 to 320 µg/mL, respectively (positive control quercetin: 374 and 180 µg/mL, respectively). Furthermore, these compounds had low IC50 values for inhibition of protein glycation (AGEs inhibition), ranging from 530 to 818 µg/mL, comparable to aminoguanidine (510 µg/mL) used as a positive control. This study resulted in the identification of seven flavonoid glycosides for the first time from the leaves of Z. oxyphylla and C. serrata with antioxidative and antiglycating activities.Entities:
Keywords: Cedrela serrata; Meliaceae; Rhamnaceae; Ziziphus oxyphylla; antiglycation; antioxidant; flavonoids
Year: 2016 PMID: 26999227 PMCID: PMC4808758 DOI: 10.3390/antiox5010009
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Flash chromatography gradient system used.
| Time (min) | Solvents | %2nd Solvent |
|---|---|---|
| 0 | AB | 0 |
| 45 | AB | 100 |
| 0.5 | BC | 0 |
| 30 | BC | 50 |
Gradient system of isolated compounds from different sub-fractions.
| ZE3 | ZE4 | CE3 | |||
|---|---|---|---|---|---|
| Time | %B | Time | %B | Time | %B |
| 0 | 30 | 0 | 30 | 0 | 30 |
| 40 | 50 | 45 | 50 | 10 | 40 |
| 44 | 100 | 49 | 100 | 20 | 40 |
| 50 | 100 | 54 | 100 | 28 | 45 |
| 52 | 30 | 56 | 30 | 30 | 100 |
| 57 | 30 | 60 | 30 | 35 | 100 |
| 37 | 30 | ||||
| 42 | 30 | ||||
Wave length = 280 nm.
DPPH radical scavenging activity (IC50, µg/mL) of different fractions of Z. oxyphylla and C. serrata.
| Chloroform | Ethyl acetate | Aq. MeOH | |||
|---|---|---|---|---|---|
| 85.0 ± 1.2 | 4740 ± 24 | 3.0 ± 0.1 | 42.1 ± 0.4 | 64.2 ± 1.1 | |
| 899.7 ± 9.4 | 473.0 ± 2.4 | 6.9 ± 0.8 | 510.5 ± 23.6 | 353.4 ± 12.1 |
DPPH radical scavenging activity (IC50, mg/mL) of sub-fractions of the ethyl-acetate fraction of Z. oxyphylla and C. serrata.
| E1 | E2 | E3 | E4 | |
|---|---|---|---|---|
| 1.43 ± 0.10 | 0.46 ± 0.09 | 0.08 ± 0.01 | 0.43 ± 0.08 | |
| 0.09 ± 0.01 | 0.08 ± 0.01 | 0.13 ± 0.03 | 0.14 ± 0.02 |
Figure 1Analytical HPLC chromatogram for ZE3 sub-fraction.
Figure 2Analytical HPLC chromatogram for ZE4 sub-fraction.
Figure 3Analytical HPLC chromatogram for CE3 sub-fraction.
Figure 4Structures for isolated compounds (1–7).
13C NMR spectral data of isolated compounds (1–3, 5–7) in CD3OD (δC, ppm, 400 MHz).
| 1 | 2 | 3 | 5 | 6 | 7 | |
|---|---|---|---|---|---|---|
| 2 | 157.1 | 158.1 | 157 | 157 | 158.0 | 156.42 |
| 3 | 134.2 | 133.8 | 135 | 135 | 135.8 | 133.20 |
| 4 | 178.3 | 178 | 178.7 | 178.7 | 179.65 | 177.53 |
| 5 | 161.7 | 161.8 | 161 | 161 | 163.2 | 161.24 |
| 6 | 98.5 | 98.5 | 98 | 98 | 99.50 | 98.85 |
| 7 | 164.6 | 164.8 | 164.4 | 164.4 | 164.70 | 164.33 |
| 8 | 93.3 | 93.4 | 94 | 94 | 94.5 | 93.76 |
| 9 | 157.6 | 157.7 | 157 | 157 | 158.40 | 156.42 |
| 10 | 104.2 | 104.1 | 104 | 104 | 105.8 | 104.01 |
| 1' | 121.3 | 121.4 | - | - | 122.6 | 120.89 |
| 2' | 131.0 | 130.9 | 116.3 | 116.3 | 116.1 | 130.96 |
| 3' | 114.7 | 114.6 | 144 | 144 | 145.8 | 115.21 |
| 4' | 160.2 | 160.1 | 148.6 | 148.6 | 149.0 | 160.10 |
| 5' | 114.7 | 114.6 | 114.6 | 114.6 | 116.7 | 115.21 |
| 6' | 131.0 | 130.9 | 121.4 | 121.4 | 122.9 | 130.96 |
| Glu-1'' | - | 102.7 | 103.8 | - | 100.87 | |
| 2'' | - | 71.6 | 71.6 | - | 74.24 | |
| 3'' | - | 75.6 | 75.6 | - | 77.58 | |
| 4'' | - | 68.4 | 68.4 | - | 69.89 | |
| 5'' | - | 73.5 | 73.5 | - | 76.46 | |
| 6'' | - | 60.4 | 60.4 | - | 60.83 | |
| Gal-1'' | 103.5 | 103.3 | - | - | - | - |
| 2'' | 71.6 | 71.8 | - | - | - | - |
| 3'' | 73.6 | 72.0- | - | - | - | - |
| 4'' | 68.6 | 69.8 | - | - | - | - |
| 5'' | 75.7 | 72.5 | - | - | - | - |
| 6'' | 60.6 | 65.5 | - | - | - | - |
| Rha-1'' | - | 100.5 | - | - | 102.7 | - |
| 2'' | - | 70.6 | - | - | 71.5 | - |
| 3'' | - | 70.6 | - | - | 72.1 | - |
| 4'' | - | 72.2 | - | - | 73.0 | - |
| 5'' | - | 68.4 | - | - | 71.3 | - |
| 6'' | - | 17.0 | - | - | 17.8 | - |
| O-coumaric | - | - | - | - | - | - |
| 1'' | - | 125.2 | - | - | - | - |
| 2'' | - | 129.9 | - | - | - | - |
| 3'' | - | 115.3 | - | - | - | - |
| 4'' | - | 159.8 | - | - | - | - |
| 5'' | - | 115.3 | - | - | - | - |
| 6'' | - | 129.9 | - | - | - | - |
| 7'' | - | 145.7 | - | - | - | - |
| 8'' | - | 113.4 | - | - | - | - |
| 9'' | - | 167 | - | - | - | - |
The symbols (') denotes the doublet found at Ring-B, i.e., Prime position whereas ('') shows the trans positions at anomeric carbons.
DPPH, superoxide, total antioxidant activity (ABTS) scavenging, and advanced glycation endproducts (AGEs) inhibitory activity of compounds 1–7 (IC50 values).
| DPPH | Superoxide | ABTS | AGEs | |
|---|---|---|---|---|
| (IC50, µg/mL) | (IC50, µg/mL) | (IC50, µg/mL) | (IC50, µg/mL) | |
| 17.8 ± 1.1 d,* | 910 ± 14 h | 230 ± 7 c | 559 ± 20 a,b,c | |
| 30.5 ± 1.9 e | 512 ± 8 f | 320 ± 9 d | 530 ± 19 a,b | |
| 10.8 ± 0.7 c | 400 ± 6 c | 170 ± 5 a | 556 ± 19 a,b,c | |
| 19.8 ± 1.2 d | 410 ± 6 c | 200 ± 6 b | 574 ± 20 b,c | |
| 18.9 ± 1.1 d | 431 ± 7 d | 180 ± 5 a | 548 ± 19 a,b,c | |
| 19.2 ± 1.2 d | 381 ± 6 b | 170 ± 5 a | 554 ± 19 a,b,c | |
| 40.4 ± 2.5 f | 482 ± 7 e | 240 ± 7 c | 818 ± 29 d | |
| 5.3 ± 0.3 a,b | 207 ± 3 a | 170 ± 5 a | 586 ± 21 b,c | |
| 8.0 ± 0.5 b | 713 ± 11 g | 170 ± 5 a | 589 ± 21 c | |
| 4.4 ± 0.3 a | 200 ± 3 a | 170 ± 5 a | 541 ± 19 a, b, c | |
| 13.4 ± 0.8 c | 410 ± 6 c | 170 ± 5 a | 593 ± 21 c | |
| Quercetin | 3.6 ± 0.6 a | 374 ± 6 b | 180 ± 5 a | not tested |
| Aminoguanidine | not tested | not tested | not tested | 510 ± 18 a |
* Different superscript letters in the same column indicate a significant difference (Tukey’s test; p = 0.05). The letters a–h denotes the comparative IC50 value of different isolated compounds with quercetin (standard drug), i.e., lower IC50 value (more activity) to higher IC50 value (less activity).